Salt Sensitivity and Left Ventricular Hypertrophy

  • Antonio Coca
  • Alejandro De la Sierra
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 432)


Coronary artery disease (CAD), congestive heart failure (CHF) and sudden death remain the most common and major complications of essential hypertension (EH)1. The Framingham study2,3 demonstrated that in 75% of all patients in whom heart failure developed, EH was the underlying disease. Moreover, EH accelerates coronary arteriosclerosis leading to myocardial ischemia in patients with genetic predisposition4, a phenomenon that exacerbates in the presence of left ventricular hypertrophy (LVH).


Essential Hypertension Left Ventricular Hypertrophy Cardiac Hypertrophy Left Ventricular Mass Ambulatory Blood Pressure Monitoring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The 1988 report of the Joint National Committee on Detection, Evaluation and treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023–1038.CrossRefGoogle Scholar
  2. 2.
    Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. Am J Card 1976; 37: 269–282.PubMedCrossRefGoogle Scholar
  3. 3.
    Kannel WB, Castelli WP, Mellumara AM, McKee PH, Fernleib M. Role of blood pressure in the development of congestive heart failure. N Eng J Med 1972; 287: 781–787.CrossRefGoogle Scholar
  4. 4.
    Chobanian AV, Brecher PI, Haudenschild CC. Effects of hypertension and antihypertensive therapy on atherosclerosis: state of the art lecture. Hypertension 1986; 8(Suppl I): 15–21.Google Scholar
  5. 5.
    Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 75(Suppl 3A): 4–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Casalle PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173–178.Google Scholar
  7. 7.
    Massie BM, Tubau JF, Szlachcic J, O’Kelly BF. Hypertensive heart disease: The critical role of left ventricular hypertrophy. J Cardiovasc Pharmacol 1989; 13(Suppl I): s18–s24.PubMedCrossRefGoogle Scholar
  8. 8.
    Messerli F, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984:; 77: 18–22.PubMedCrossRefGoogle Scholar
  9. 9.
    McLenechan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Eng J Med 1987; 317: 787–792.CrossRefGoogle Scholar
  10. 10.
    Kannel WB, D’Agostino RB, Levy D, Belanger AJ. Prognostic significance of regression of left ventricular hypertrophy. Circulation 1988; 78(suppl II): 89 (abstract).Google Scholar
  11. 11.
    Tarazi RC. The hemodynamics of hypertension. In: Genest J, Kuchel O, Hamet P, Cantin M Eds. Hypertension: Physiopathology and treatment. New York: McGraw-Hill, 1983; 15–42.Google Scholar
  12. 12.
    Grossman W, Jones D, Mc Laurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Tarazi RC. Cardiovascular hypertrophy in hypertension. Hypertension 1986; 8(Suppl II): 187–190.Google Scholar
  14. 14.
    Mulvany MJ, Korsgaard N. Correlation and otherwise between blood pressure, cardiac mass and resistance vessel characteristics in hypertensive, normotensive and hypertensive/normotensive hybrid rats. J Hypertens 1983; 1: 235–244.PubMedCrossRefGoogle Scholar
  15. 15.
    Sen S. Regression of cardiac hypertrophy: experimental animal model. Am J Med 1983; 75(Suppl 3A): 87–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Tarazi RC, Fouad FM. Reversal of cardiac hypertrophy by medical treatment. Annu Rev Med 1985; 36: 407–414.PubMedCrossRefGoogle Scholar
  17. 17.
    Folkow B. Cardiovascular structural adaptation: its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med 1978; 55(Suppl): 3s–22s.Google Scholar
  18. 18.
    Nuñez BD, Messerli FH, Amadeo C, et al. Biventricular cardiac hypertrophy in essential hypertension. Am Heart J 1987; 114: 813–818.PubMedCrossRefGoogle Scholar
  19. 19.
    Yamori Y, Mori C, Nishio T, et al. Cardiac hypertrophy in early hypertension. Am J Cardiol 1979; 44: 964–969.PubMedCrossRefGoogle Scholar
  20. 20.
    Radice M, Alli C, Avanzini F, et al. Left ventricular structure and function in normotensive adolescents with a genetic predisposition to hypertension. Am Heart J 1986; 111: 115–120.PubMedCrossRefGoogle Scholar
  21. 21.
    Frohlich ED, Tarazi RC. Is arterial pressure the role factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol 1979; 44: 959–963.PubMedCrossRefGoogle Scholar
  22. 22.
    Frohlich ED. The heart in hypertension, In: Genest J, Kuchel O, Hamet P, Cantin M, Eds. Hypertension: Physiopathology and treatment. New York. McGraw-Hill, 1983; 791–810.Google Scholar
  23. 23.
    Simpson P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cell is an alpha-1-adrenergic response. J Clin Invest 1983; 72: 732–738.PubMedCrossRefGoogle Scholar
  24. 24.
    Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control. Am J Cardiol 1982; 49: 795–801.PubMedCrossRefGoogle Scholar
  25. 25.
    Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991; 9: 3–15.PubMedGoogle Scholar
  26. 26.
    Sen S, Tarazi RC, Bumpus FM. Cardiac effects of angiotensin-antagonists in normotensive rats. Clin Sci 1979; 56: 439–444.PubMedGoogle Scholar
  27. 27.
    Ferrano CM. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension: An Overview. Drugs 1990; 39(Suppl 2): 1–8.Google Scholar
  28. 28.
    Meggs LG, Ben-Ari J, Gummon D, Gordman AA. Myocardial hypertrophy: The effect of sodium and the role of sympathetic nervous activity. Am J Hypertens 1988; 1: 11–15.PubMedGoogle Scholar
  29. 29.
    De Simone G, Devereux RB, Camargo MJF, Wallerson DC, Sealey JE, Laragh JH. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996; 9: 216–222.PubMedCrossRefGoogle Scholar
  30. 30.
    Schmieder RE, Messerli FH, Garaveglia GE, Nunez BE. Dietary salt intake: a determinant of cardiac involvement in essential hypertension. Circulation 1988; 78: 951–956.PubMedCrossRefGoogle Scholar
  31. 31.
    Du Cailar G, Ribstein J, Grolleau R, Mimran A: Influence of sodium intake on left ventricular structure in untreated essential hypertensives. J Hypertens 1989; 7(suppl 6): S258–S259.Google Scholar
  32. 32.
    Heimann JC, Drumond S, Rodrigues AT, Guedes AJ, Dichtchekenian V, Marcondes M. Left ventricular hypertrophy is more marked in salt-sensitive than in salt-resistant hypertensive patients. J Cardiovasc Pharmacol 1991; 17(suppl 2): 122–124.CrossRefGoogle Scholar
  33. 33.
    Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM: Microalbuminuria in salt-sensitive patients. A marker for renal and cardiovascular risk factors. Hypertension 1994; 23: 195–199.PubMedCrossRefGoogle Scholar
  34. 34.
    Sahn DJ, De Maria A, Kisslo J, Weyman A: The committee on M-mode standardization of the American society: recommendations regarding quantitation in M-mode echocardiography. Circulation 1978; 58:1071–1083.Google Scholar
  35. 35.
    Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613–618.PubMedCrossRefGoogle Scholar
  36. 36.
    Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–352.PubMedGoogle Scholar
  37. 37.
    De la Sierra A, Lluch MM, Coca A, et al: Assessment of salt-sensitivity in essential hypertension by twenty-four hour ambulatory blood pressure monitoring. Am J Hypertens 1995; 8: 970–977.PubMedCrossRefGoogle Scholar
  38. 38.
    De la Sierra A, Lluch MM, Paré JC, Coca A, Aguilera MT, Azqueta M. Increased left ventricular mass in salt-sensitive hypertensive patients. J Hum Hypertens 1996; in press.Google Scholar
  39. 39.
    Campese VM, Romoff MS, Levitan D, et al. Abnormal relationship between salt intake and sympathetic nervous system activity in salt-sensitive patients with essential hypertension. Kidney Int 1982; 21: 371–378.PubMedCrossRefGoogle Scholar
  40. 40.
    Limon I, Blanc J, Koutouzov S, Knorr A, Meyer P, Marche P. Platelet phospholipase C activity in saltdependent hypertension. Hypertension 1990; 15: 381–387.PubMedCrossRefGoogle Scholar
  41. 41.
    Campese VM: Salt sensitivity in hypertension. Renal and cardiovacular implications. Hypertension 1994; 23: 531–550.PubMedCrossRefGoogle Scholar
  42. 42.
    De la Sierra A, Lluch MM, Coca A, et al: Fluid, ionic and hormonal changes induced by high salt intake in salt-sensitive and salt-resistant hypertensive patients. Clin Sci 1996; 91: 155–61.PubMedGoogle Scholar
  43. 43.
    Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 823–825.Google Scholar
  44. 44.
    Simpson P: Norepinephrine-stimulated hypertrophy of culture rat myocardial cell is an alpha-adrenergic response. J Clin Invest 1983; 72: 732–738.PubMedCrossRefGoogle Scholar
  45. 45.
    Luft FC, Rankin LI, Henry DP, et al: Plasma and urinary norepinephrine values at extremes of Na+ intake in normal man. Hypertension 1979; 1: 261–266.PubMedCrossRefGoogle Scholar
  46. 46.
    Koolen MI, van Brummelen PV: Adrenergic activity and pheripheral hemodynamics in relation to sodium sensitivity in patients with essential hypertension. Hypertension 1984; 6: 820–825.PubMedCrossRefGoogle Scholar
  47. 47.
    De la Sierra A, Coca A, Paré JC, Sànchez M, Valls V, Urbano-Márquez A. Erythrocyte ion fluxes in essential hypertensive patients with left ventricular hypertrophy. Circulation 1993; 88: 1628–1633.PubMedCrossRefGoogle Scholar
  48. 48.
    Navarro F, Coca A, Paré JC, De la Sierra A, Bosch X, Urbano-Márquez A. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity. Eur Heart Journal 1993; 14(Suppl J): 38–41.Google Scholar
  49. 49.
    Coca A, De la Sierra A, Urbano-Márquez A. Ion Transport and left ventricular hypertrophy in essential hypertension. In: A. Coca and R.P. Garay (Eds). Ion Transport in Hypertension. New Perspectives. CRC Press, Boca Raton, Florida (USA), 1994: 247–272.Google Scholar
  50. 50.
    Lluch MM, De la Sierra A, Poch E, Coca A, Aguilera MT, Compte M, Urbano-Márquez A. Erythrocyte sodium transport, intraplatelet pH, and calcium concentration in salt-sensitive hypertension. Hypertension 1996; 27: 919–925.PubMedCrossRefGoogle Scholar
  51. 51.
    Inoue I, Matsuura H, Shingu T, et al. Role of intracellular cation abnormalities in development of left ventricular hypertrophy. J Cardiovasc Pharmacol 1991; 17(suppl 2): 107–109.CrossRefGoogle Scholar
  52. 52.
    Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801.PubMedCrossRefGoogle Scholar
  53. 53.
    Sharma AM, Ruland K, Spies KP, Distler A: Salt sensitivity in young normotensive subjects is associated with a hyperinsulinemic response to oral glucose. J Hypertens 1991; 9: 329–335.PubMedCrossRefGoogle Scholar
  54. 54.
    Sharma AM, Schorr U, Distler A: Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 1993; 21: 273–279.PubMedCrossRefGoogle Scholar
  55. 55.
    Falkner B, Hulman S, Kushner H: Hyperinsulinemia and blood pressure sensitivity to sodium in young blacks. J Am Soc Nephrol 1992; 3: 940–946.PubMedGoogle Scholar
  56. 56.
    Bigazzi R, Bianchi S, Baldari G, Campese VM: Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: role of insulin. Am J Hypertens 1996; 9: 24–32.PubMedCrossRefGoogle Scholar
  57. 57.
    Weir MR. Insulin resistance and salt sensitivity. A renal hemodynamic abnormality? Am J Hypertens 1996; 9: 193s–199s.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Antonio Coca
    • 1
  • Alejandro De la Sierra
    • 1
  1. 1.Hypertension Unit Department of Internal Medicine Hospital ClinicoUniversity of BarcelonaBarcelonaSpain

Personalised recommendations